PubMed

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.

Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG.

Curr Med Res Opin. 2008 Jan;24(1):275-86.PMID: 18053320 [PubMed - indexed for MEDLINE]Related articles

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.

Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Maggs DG, Wintle ME.

Clin Ther. 2007 Jan;29(1):139-53.PMID: 17379054 [PubMed - indexed for MEDLINE]Related articles

Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin.

Riddle MC, Henry RR, Poon TH, Zhang B, Mac SM, Holcombe JH, Kim DD, Maggs DG.

Diabetes Metab Res Rev. 2006 Nov-Dec;22(6):483-91.PMID: 16634116 [PubMed - indexed for MEDLINE]Related articles

The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes.

Amiel SA, Heller SR, Macdonald IA, Schwartz SL, Klaff LJ, Ruggles JA, Weyer C, Kolterman OG, Maggs DG.

Diabetes Obes Metab. 2005 Sep;7(5):504-16.PMID: 16050943 [PubMed - indexed for MEDLINE]Related articles

Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets.

Ratner R, Whitehouse F, Fineman MS, Strobel S, Shen L, Maggs DG, Kolterman OG, Weyer C.

Exp Clin Endocrinol Diabetes. 2005 Apr;113(4):199-204.PMID: 15891954 [PubMed - indexed for MEDLINE]Related articles

Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes.

Ceriello A, Piconi L, Quagliaro L, Wang Y, Schnabel CA, Ruggles JA, Gloster MA, Maggs DG, Weyer C.

Diabetes Care. 2005 Mar;28(3):632-7.PMID: 15735200 [PubMed - indexed for MEDLINE]Related articlesFree article

Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.

Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, Weyer C, Kolterman OG.

Diabet Med. 2004 Nov;21(11):1204-12.PMID: 15498087 [PubMed - indexed for MEDLINE]Related articles

Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients.

Hollander P, Maggs DG, Ruggles JA, Fineman M, Shen L, Kolterman OG, Weyer C.

Obes Res. 2004 Apr;12(4):661-8.PMID: 15090634 [PubMed - indexed for MEDLINE]Related articles

Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.

Maggs DG, Fineman M, Kornstein J, Burrell T, Schwartz S, Wang Y, Ruggles JA, Kolterman OG, Weyer C.

Diabetes Metab Res Rev. 2004 Jan-Feb;20(1):55-60.PMID: 14737746 [PubMed - indexed for MEDLINE]Related articles

Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.

Weyer C, Gottlieb A, Kim DD, Lutz K, Schwartz S, Gutierrez M, Wang Y, Ruggles JA, Kolterman OG, Maggs DG.

Diabetes Care. 2003 Nov;26(11):3074-9.PMID: 14578242 [PubMed - indexed for MEDLINE]Related articlesFree article

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.

Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG.

Diabetes Care. 2003 Mar;26(3):784-90.PMID: 12610038 [PubMed - indexed for MEDLINE]Related articlesFree article

Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.

Levetan C, Want LL, Weyer C, Strobel SA, Crean J, Wang Y, Maggs DG, Kolterman OG, Chandran M, Mudaliar SR, Henry RR.

Diabetes Care. 2003 Jan;26(1):1-8.PMID: 12502651 [PubMed - indexed for MEDLINE]Related articlesFree article

The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.

Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG.

Horm Metab Res. 2002 Sep;34(9):504-8.PMID: 12384827 [PubMed - indexed for MEDLINE]Related articles

The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.

Fineman MS, Koda JE, Shen LZ, Strobel SA, Maggs DG, Weyer C, Kolterman OG.

Metabolism. 2002 May;51(5):636-41.PMID: 11979398 [PubMed - indexed for MEDLINE]Related articles

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.

Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman OG.

Diabetes Care. 2002 Apr;25(4):724-30.PMID: 11919132 [PubMed - indexed for MEDLINE]Related articlesFree article

Striking differences in glucose and lactate levels between brain extracellular fluid and plasma in conscious human subjects: effects of hyperglycemia and hypoglycemia.

Abi-Saab WM, Maggs DG, Jones T, Jacob R, Srihari V, Thompson J, Kerr D, Leone P, Krystal JH, Spencer DD, During MJ, Sherwin RS.

J Cereb Blood Flow Metab. 2002 Mar;22(3):271-9.PMID: 11891432 [PubMed - indexed for MEDLINE]Related articlesFree article

Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control.

Weyer C, Maggs DG, Young AA, Kolterman OG.

Curr Pharm Des. 2001 Sep;7(14):1353-73. Review. Erratum in: Curr Pharm Des 2001 Dec;7(18):1967. PMID: 11472273 [PubMed - indexed for MEDLINE]Related articles

Effect of insulin on glycerol production in obese adolescents.

Robinson C, Tamborlane WV, Maggs DG, Enoksson S, Sherwin RS, Silver D, Shulman GI, Caprio S.

Am J Physiol. 1998 Apr;274(4 Pt 1):E737-43.PMID: 9575836 [PubMed - indexed for MEDLINE]Related articlesFree article

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI.

N Engl J Med. 1998 Mar 26;338(13):867-72.PMID: 9516221 [PubMed - indexed for MEDLINE]Related articlesFree article

Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.

Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI.

Ann Intern Med. 1998 Feb 1;128(3):176-85.PMID: 9454525 [PubMed - indexed for MEDLINE]Related articlesFree article

The adipose tissue/central nervous system axis.

Loftus TM, Maggs DG, Lane MD.

Diabetologia. 1997 Oct;40 Suppl 3:B16-20. No abstract available. PMID: 9345640 [PubMed - indexed for MEDLINE]Related articles

Mechanisms of the sympathoadrenal response to hypoglycemia.

Maggs DG, Sherwin RS.

Adv Pharmacol. 1998;42:622-6. No abstract available. PMID: 9327979 [PubMed - indexed for MEDLINE]Related articles

Microdialysis techniques in the study of brain and skeletal muscle.

Maggs DG, Borg WP, Sherwin RS.

Diabetologia. 1997 Jul;40 Suppl 2:S75-82. Review.PMID: 9248705 [PubMed - indexed for MEDLINE]Related articles

Counterregulation in peripheral tissues: effect of systemic hypoglycemia on levels of substrates and catecholamines in human skeletal muscle and adipose tissue.

Maggs DG, Jacob R, Rife F, Caprio S, Tamborlane WV, Sherwin RS.

Diabetes. 1997 Jan;46(1):70-6.PMID: 8971084 [PubMed - indexed for MEDLINE]Related articles

Interstitial fluid concentrations of glycerol, glucose, and amino acids in human quadricep muscle and adipose tissue. Evidence for significant lipolysis in skeletal muscle.

Maggs DG, Jacob R, Rife F, Lange R, Leone P, During MJ, Tamborlane WV, Sherwin RS.

J Clin Invest. 1995 Jul;96(1):370-7.PMID: 7615807 [PubMed - indexed for MEDLINE]Related articlesFree article

Thermoregulatory responses to hyperinsulinemic hypoglycemia and euglycemia in humans.

Maggs DG, Scott AR, MacDonald IA.

Am J Physiol. 1994 Nov;267(5 Pt 2):R1266-72.PMID: 7977853 [PubMed - indexed for MEDLINE]Related articles

Physiological and symptomatic responses to postural change in non-diabetic subjects during hypoglycaemia.

Maggs DG, MacDonald IA.

Clin Sci (Lond). 1994 Aug;87(2):193-9.PMID: 7924164 [PubMed - indexed for MEDLINE]Related articles

Thermoregulatory responses to hyperinsulinaemic hypoglycaemia and euglycaemia in IDDM.

Maggs DG, Macdonald IA, Tattersall RB.

Diabetologia. 1994 Jul;37(7):689-96.PMID: 7958540 [PubMed - indexed for MEDLINE]Related articles

Metabolic heat production and cardiovascular responses to an incremental intravenous infusion of adrenaline in healthy subjects.

Maggs DG, Gallen IW, Fone K, Macdonald IA.

Clin Auton Res. 1994 Jun;4(3):131-6.PMID: 7994166 [PubMed - indexed for MEDLINE]Related articles

Does ethanol cause hypoglycaemia in overnight fasted patients with type 1 diabetes?

Moriarty KT, Maggs DG, Macdonald IA, Tattersall RB.

Diabet Med. 1993 Jan-Feb;10(1):61-5.PMID: 8435990 [PubMed - indexed for MEDLINE]Related articles